Galectin Therapeutics Inc (GALT) stock
GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.91−0.11 (-3.64%)
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
Galectin Therapeutics cash
Cash and short-term investments held at the end of each period.
Galectin Therapeutics's cash was $13.27M at Jun 30, 2026. For fiscal 2025 it was $17.72M, up 17.2% from the year before. Over ten years it grew -3.7% a year on average. The highest annual figure on record is $47.48M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.72M | +17.2% |
| FY2024 | Dec 31, 2024 | $15.12M | -41.1% |
| FY2023 | Dec 31, 2023 | $25.66M | +38.0% |
| FY2022 | Dec 31, 2022 | $18.59M | -53.1% |
| FY2021 | Dec 31, 2021 | $39.65M | +46.1% |
| FY2020 | Dec 31, 2020 | $27.14M | -42.8% |
| FY2019 | Dec 31, 2019 | $47.48M | +475.3% |
| FY2018 | Dec 31, 2018 | $8.25M | +170.3% |
| FY2017 | Dec 31, 2017 | $3.05M | -80.1% |
| FY2016 | Dec 31, 2016 | $15.36M | -40.6% |
| FY2015 | Dec 31, 2015 | $25.85M | -11.3% |
| FY2014 | Dec 31, 2014 | $29.13M | +177.7% |
| FY2013 | Dec 31, 2013 | $10.49M | +12.0% |
| FY2012 | Dec 31, 2012 | $9.36M | +46.4% |
| FY2011 | Dec 31, 2011 | $6.40M | +8.6% |
| FY2010 | Dec 31, 2010 | $5.89M | +2247.0% |
| FY2009 | Dec 31, 2009 | $251.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.27M | -3.6% |
| Q1 FY2026 | Mar 31, 2026 | $14.11M | +89.9% |
| Q4 FY2025 | Dec 31, 2025 | $17.72M | +17.2% |
| Q3 FY2025 | Sep 30, 2025 | $11.53M | -57.4% |
| Q2 FY2025 | Jun 30, 2025 | $13.77M | -46.2% |
| Q1 FY2025 | Mar 31, 2025 | $7.43M | -68.5% |
| Q4 FY2024 | Dec 31, 2024 | $15.12M | -41.1% |
| Q3 FY2024 | Sep 30, 2024 | $27.06M | +32.9% |
| Q2 FY2024 | Jun 30, 2024 | $25.60M | +42.5% |
| Q1 FY2024 | Mar 31, 2024 | $23.56M | +30.9% |
| Q4 FY2023 | Dec 31, 2023 | $25.66M | +38.0% |
| Q3 FY2023 | Sep 30, 2023 | $20.36M | +28.6% |
| Q2 FY2023 | Jun 30, 2023 | $17.97M | -25.7% |
| Q1 FY2023 | Mar 31, 2023 | $18.00M | -43.1% |
| Q4 FY2022 | Dec 31, 2022 | $18.59M | -53.1% |
| Q3 FY2022 | Sep 30, 2022 | $15.83M | -56.7% |
| Q2 FY2022 | Jun 30, 2022 | $24.18M | -23.5% |
| Q1 FY2022 | Mar 31, 2022 | $31.61M | +52.2% |
| Q4 FY2021 | Dec 31, 2021 | $39.65M | +46.1% |
| Q3 FY2021 | Sep 30, 2021 | $36.60M | +12.4% |
| Q2 FY2021 | Jun 30, 2021 | $31.60M | -22.5% |
| Q1 FY2021 | Mar 31, 2021 | $20.76M | -52.1% |
| Q4 FY2020 | Dec 31, 2020 | $27.14M | -42.8% |
| Q3 FY2020 | Sep 30, 2020 | $32.56M | -35.3% |
| Q2 FY2020 | Jun 30, 2020 | $40.77M | -21.7% |
| Q1 FY2020 | Mar 31, 2020 | $43.33M | +521.5% |
| Q4 FY2019 | Dec 31, 2019 | $47.48M | +475.3% |
| Q3 FY2019 | Sep 30, 2019 | $50.34M | +396.6% |
| Q2 FY2019 | Jun 30, 2019 | $52.04M | +395.8% |
| Q1 FY2019 | Mar 31, 2019 | $6.97M | +74.8% |
| Q4 FY2018 | Dec 31, 2018 | $8.25M | +170.3% |
| Q3 FY2018 | Sep 30, 2018 | $10.14M | +45.7% |
| Q2 FY2018 | Jun 30, 2018 | $10.50M | +15.0% |
| Q1 FY2018 | Mar 31, 2018 | $3.99M | -70.8% |
| Q4 FY2017 | Dec 31, 2017 | $3.05M | -80.1% |
| Q3 FY2017 | Sep 30, 2017 | $6.96M | -56.7% |
| Q2 FY2017 | Jun 30, 2017 | $9.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $13.64M | – |
| Q4 FY2016 | Dec 31, 2016 | $15.36M | – |
| Q3 FY2016 | Sep 30, 2016 | $16.06M | – |
See a number that looks wrong?